[Situation and problems of the research-oriented pharmaceutical industry (author's transl)].
The inherent factors in the drug development strategy of a research-oriented pharmaceutical company, the actualities of the pharmaceutical market and the interdependence of the different determinants in terms of their meaning for innovation potential are presented. The applicability and the specificity of animal experimental results in regard to their human clinical relevance are particularly indicated as well as the reasons which in the future will narrow the chances for real and realizeable therapeutic advances in the area of psychotropic substances. Exaggerated, unrealistic and/or scientifically non-convincing requirements from the authorities can be an important inhibitory factor. For the main groups of psychotropic substances a series of desirable elements are enumerated and, at the same time, the chances for innovation are formulated. With the aim of improving the chances for innovation it is postulated to search for possibilities of a more rapid and more efficient feed-back from the clinic. Indeed this should be an integrated part of the activities in the early phases of development of new products.